We recently announced the commencement of head-to-head trial of VYVANSE versus Concerta. If you remember, when Jeff talked about European filing, he referred to that having a reference on in one of the studies. That came out, if you remember, with a very favorable comparison. And on the base of that, we feel very empowered now to conduct a full head-to-head study versus Concerta. You may ask why we're doing that at this stage of the product's life cycle. Simply put, it's to demonstrate to payors around the world as we contemplate the rolling out of VYVANSE on a global basis. But this is by far in a way, the best product in the class and offers best value to both patients and payors all over the world.We're also ongoing with our enrollment in our major depressive disorder study, the first lead of our new uses of VYVANSE programs. And we also, today, have reported headline data from -- positive findings on headline data from a new Phase II study in binge eating disorder, and Jeff will be commenting on that in more detail later in his presentation.
Shire's CEO Discusses Q1 2012 Results - Earnings Call Transcript
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.